Main content

    Neuroendocrine Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Active Trials

    Title: A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
    Description: This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who have histologically or pathologically confirmed locally unresectable or metastatic low or intermediate grade pancreatic neuroendocrine tumor, excluding small cell carcinoma
    Status: Call site for study status
    Contact: Laurel Brechtel, 415-600-1654, Email: about Study ECOG E2211

    • updated October 2014

    Back to top